Related references
Note: Only part of the references are listed.Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms
Francesca Borgna et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up
Anna Sundlov et al.
NEUROENDOCRINOLOGY (2021)
Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
Jakob Albrecht et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
Rosalba Mansi et al.
PHARMACEUTICALS (2021)
Recombinant botulinum neurotoxin serotype A1 in vivo characterization
Cindy Perier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Marcus Ruscetti et al.
CELL (2020)
The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
Jie Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
Carleen Cullinane et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
J. Capdevila et al.
ANNALS OF ONCOLOGY (2020)
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Senescent Cells in Cancer Therapy: Friends or Foes?
Boshi Wang et al.
TRENDS IN CANCER (2020)
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
Diane Reidy-Lagunes et al.
CLINICAL CANCER RESEARCH (2019)
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Satya Das et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
Simone U. Dalm et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease
Rikke Nielsen et al.
KIDNEY INTERNATIONAL (2016)
Analysis of 177Lu-DOTA-Octreotate Therapy-Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
Franziska Graf et al.
PLOS ONE (2014)
Chloroquine causes similar electroretinogram modifications, neuronal phospholipidosis and marked impairment of synaptic vesicle transport in Albino and Pigmented Rats
Stephane Lezmi et al.
TOXICOLOGY (2013)
Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
Renzo Cescato et al.
MOLECULAR ENDOCRINOLOGY (2010)
H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy
Monika Podhorecka et al.
JOURNAL OF NUCLEIC ACIDS (2010)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Mihaela Ginj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)